Cingulate Inc. Share Price
CINGCingulate Inc. Stock Performance
Open $3.90 | Prev. Close $3.97 | Circuit Range N/A |
Day Range $3.81 - $3.97 | Year Range $3.23 - $5.97 | Volume 2,230 |
Average Traded $3.88 |
Cingulate Inc. Share Price Chart
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
04-Dec-25 | $3.90 | $3.97 | +0.00% |
04-Dec-25 | $3.90 | $3.97 | +1.02% |
02-Dec-25 | $3.82 | $3.93 | +7.82% |
01-Dec-25 | $3.65 | $3.65 | -1.88% |
28-Nov-25 | $3.67 | $3.71 | +1.23% |
26-Nov-25 | $3.67 | $3.67 | +1.24% |
25-Nov-25 | $3.45 | $3.63 | +1.83% |